SCHEMBL4254591

SCHEMBL4254591

Cn1c(=O)c2c(c3ccccc31)OC(N)=C(C#N)C2c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
HTT P42858 1/20 0.54
MAPT P10636 11/20 0.51
ALDH1A1 P00352 6/20 0.50
KMT2A Q03164 6/20 0.49
KDM4E B2RXH2 6/20 0.49
MEN1 O00255 4/20 0.49
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
TSHR P16473 1/20 0.48
POLB P06746 2/20 0.48
NPC1 O15118 1/20 0.48
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MYB P10242 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249301 0.91 MAPT (0.63) SMN1; SMN2HTTMAPTALDH1A1KMT2A
SCHEMBL4256965 0.89 MAPT (0.51) TP53SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL4256943 0.89 KDM4E (0.65) SMN1; SMN2HTTMAPTALDH1A1KMT2A
SCHEMBL4255032 0.89 MAPT (0.59) TP53SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL4253512 0.89 MAPT (0.66) TP53SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL4255338 0.88 SMN1; SMN2 (0.47) TP53SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL4259180 0.87 MAPT (0.49) TP53SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL4259370 0.86 KDM4E (0.50) TP53SMN1; SMN2HTTMAPTALDH1A1
SCHEMBL4252501 0.86 MEN1 (0.55) SMN1; SMN2HTTMAPTALDH1A1KMT2A
SCHEMBL4249281 0.86 POLB (0.62) SMN1; SMN2HTTMAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349864-B2 Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof BAX, CASP3, CASP7 TP53 54/4885SMN1; SMN2 1792/4885HTT 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.